Investigational drug · Phase 2
LY4065967
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Chronic Pain, Diabetic Peripheral Neuropathic Pain, Osteoarthritis, Knee.
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 4, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
3
3 still active
All registered trials
7
Any phase or sponsor naming "LY4065967"
First trial start
2026
Feb 16, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "LY4065967", any sponsor or status.
Conditions studied
As listed on its trial records.
- Chronic Pain
- Diabetic Peripheral Neuropathic Pain
- Osteoarthritis, Knee
- Low Back Pain
Approved drugs for the same conditions: Neuropathic pain · Osteoarthritis · Cardiovascular and metabolic · Neurology · Pain and anesthesia
Largest trials
Live from ClinicalTrials.gov: studies naming "LY4065967" as an intervention, largest first.
- A Master Protocol Study (LY900028) of Multiple Intervention-Specific-Appendices (ISAs) in Participants With Chronic PainPivotal-lookingRecruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT05986292 · 10,000 participants (planned) · Start Jan 30, 2020 · Primary completion Apr 2027
Drug: LY3016859 ISA; LY3556050 ISA and 5 more · For: Osteoarthritis, Knee; Diabetic Neuropathic Pain; Chronic Low-back Pain
Sites: Birmingham, Alabama; Glendale, Arizona; Phoenix, Arizona · 64 sites in all
- A Chronic Pain Master Protocol (CPMP): A Study of LY4065967 in Participants With Osteoarthritis PainPivotal-lookingRecruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT07641517 · 150 participants (planned) · Start Jun 25, 2026 · Primary completion Apr 2027
Drug: LY4065967; Placebo · For: Osteoarthritis, Knee; Chronic Pain
Sites: Birmingham, Alabama; Phoenix, Arizona; Palm Springs, California · 36 sites in all
- A Chronic Pain Master Protocol (CPMP): A Study of LY4065967 in Participants With Diabetic Peripheral Neuropathic PainPivotal-lookingRecruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT07285018 · 150 participants (planned) · Start Feb 16, 2026 · Primary completion Jul 2027
Drug: LY4065967; Placebo · For: Diabetic Peripheral Neuropathic Pain
Sites: Birmingham, Alabama; Phoenix, Arizona; Palm Springs, California · 36 sites in all
- A Chronic Pain Master Protocol (CPMP): A Study of LY4065967 in Participants With Chronic Low Back PainPivotal-lookingRecruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT07641504 · 150 participants (planned) · Start Aug 12, 2026 · Primary completion Apr 2027
Drug: LY4065967; Placebo · For: Chronic Pain; Low Back Pain
Sites: Birmingham, Alabama; Phoenix, Arizona; Palm Springs, California · 36 sites in all
Eli Lilly and CompanyEli Lilly (LLY)
NCT06594159 · 59 participants · Start Oct 22, 2024 · Primary completion Mar 11, 2025
Drug: LY4065967; Placebo and 1 more · For: Healthy
Sites: Fukuoka, Japan
Eli Lilly and CompanyEli Lilly (LLY)
NCT07607483 · 36 participants · Start Jun 3, 2026 · Primary completion Jul 27, 2026
Drug: LY4065967 Tablet; LY4065967 Formulated Capsule and 1 more · For: Healthy
Sites: Daytona Beach, Florida; Dallas, Texas
Eli Lilly and CompanyEli Lilly (LLY)
NCT07039045 · 16 participants · Start Jun 23, 2025 · Primary completion Aug 16, 2025
Drug: LY4065967 · For: Healthy
Sites: Madison, Wisconsin
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Chronic Pain
- CebranopadolTRN-228Phase 34 trials
Adneuris Therapeutics, Inc. · Pain, Acute Pain, Chronic Pain
- ST-01Phase 21 trial
Sustained Therapeutics Inc. · Chronic Pain
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Eli Lilly.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.